PRINCIPLES OF INSULIN THERAPY
|
|
- Anthony Matthews
- 5 years ago
- Views:
Transcription
1 08 PRINCIPLES OF INSULIN THERAPY 8.1 GENERAL PRINCIPLES Indications of Insulin Therapy The classical type 1 diabetes mellitus and LADA cases Hyperglycemic emergencies (DKA, HHS) Some cases of type 2 diabetes mellitus GDM not controlled with diet and physical activity Mechanism of Insulin Action Stimulates entry of glucose into the cells Increases glycogen storage Inhibits hepatic glucose output Inhibits the degradation of fat and protein Insulin Sources Recombinant DNA technique (human insulin, insulin analogues) Traditional bovine and porcine insulins Semi-synthetic insulin obtained from porcine insulin (not used in our country) Insulin Absorption Insulin absorption may be different on individual basis due to the reasons listed below: Insulin source: Compared to animal insulin, human insulin has a shorter duration of action. There are some differences depending on manufacturer (NovoNordisk, Eli Lilly and Sanofi-Aventis) Injection site: From the fastest to the slowest absorbing site: insulin could be injected s.c. into upper abdomen (epigastrium), upper arms, thighs, and buttocks. Environmental temperature: The warm temperature is associated with higher insulin absorption compared to cold temperature. Exercise, systemic fever and massage to the injection site increase insulin absorption. 40
2 Turk JEM 2010; 14: Suppl 40-6 The Principles of Insulin Therapy Insulin Preparations A. Insulin Strength Insulin preparations available in Turkey and used globally contain 100 IU insulin in 1 ml and called as U-100-insulins. Also U-500 insulins can be used in patients with marked insulin resistance and insulin requirement in some European countries and USA). B. Types and Action Profile of Insulins The following table shows currently available insulin preparations and their action profiles (Table 8.1). Although insulin does not pass through the placenta, there is not enough data available about the use of long-acting insulin analogs in pregnancy. Table 8.1 Types and action profiles of insulin preparations Insulin type Generic name Trade name Onset of Peak action (h) Duration action (min) of action (h) Short-acting (Regular) insulin Human regular insulin Actrapid HM, Humulin R Rapid-acting insulins Glulisine insulin Apidra (Prandial analogs) Lispro insulin Humalog Aspart insulin NovoRapid Intermediate -acting (NPH) insulin NPH human insulin Humulin N Insulatard HM Long-acting insulins (*) Glargine insulin Lantus (Basal analogs) Detemir insulin Levemir 60 Peakless (**) Premixed (biphasic) human insulin 30% regular + 70% Humulin M 70/30 (Regular + NPH) NPH human insulin Mixtard HM Variable Premixed analogs 25% insulin lispro + Humalog Mix25 (Biphasic lispro + NPL) 75% insulin lispro protamin 50% insulin lispro + Humalog Mix Variable % insulin lispro protamin Premixed analogs 30% insulin aspart + NovoMix Variable (*) Long-acting (basal) analogs are not equivalent in efficiency. When used as basal insulin the requirement for glargine is at least 10 to 15% less than that for detemir. Insulin detemir shows slightly less day to day variation and less weight gain effect (0.5-1 kg) than glargine. The duration of action of insulin detemir shortens at low doses, therefore especially type 1 diabetes patients with <0.35 IU/kg/day basal insulin requirement may need a second basal dose Routes of Insulin Delivery Insulin is normally injected subcutaneously. In case of emergency rapid- or short-acting insulins can be given intramuscularly or intravenously Insulin Dose Adjustment Aim To mimic normal basal insulin secretion in people with type 1 diabetes (insulin replacement) Some cases with type 2 diabetes may need (basal) insulin support, and the need for insulin replacement arises over time Insulin Indications in Type 2 Diabetes Failing to obtain good metabolic control with submaximal doses of OADs Excessive weight loss Severe hypoglycemia symptoms
3 42 The Principles of Insulin Therapy Turk JEM 2010; 14: Suppl 40-6 Acute MI Acute diseases with fever, systemic diseases Hyperosmolar hyperglycemic state (HHS) and ketotic coma (DKA) Major surgical operation Pregnancy and lactation Kidney or liver failure Severe allergy or side-effects to any OADs Severe insulin resistance (with acanthosis nigricans) Complications of nsulin Treatment Hypoglycemia: The main and most frequent complication during therapy with insulin is hypoglycemia. It is associated with strict glycemic control and longer duration of diabetes. It is more frequent in type 1 diabetic patients treated with basal-bolus insulin regimen. In DCCT study the frequency of hypoglycemia is 3 times higher in intensive insulin therapy group compared to conventional treatment group. Risk of hypoglycemia with insulin analogues is slightly lower than human insulins. Weight gain: At the beginning of insulin therapy few kilograms of weight gain is expected due to the regaining of previously lost adipose and muscle tissue, and the disappearance of glucosuria. Then the fear of hypoglycemia and unbalanced diet may cause continued weight gain. Massive hepatomegaly: It is associated with excessive glycogen storage in the liver, and is rare nowadays. Edema: Increased sodium reabsorption and decreased osmotic diuresis due to insulin may increase body fluid volume at the beginning of treatment. Anti-insulin antibodies and allergy to insulin: Both are rare complications nowadays with availability of human insulins and new insulin analogues. Lipoatrophy: It is a rare immunological event with newer pure insulins. Lipohypertrophy: It occurs when the same injection site is used too frequently, and can be treated by rotating the injection sites. Bleeding, leakage and pain: Bleeding can be prevented by administrating injection to a region which is not rich in capillary vessels. Leakage is minimized by using long needle and by releasing the pinch 5 to 10 seconds before removing the needle from the skin. Especially acid insulins, such as glargine, may cause slight and unimportant pain at the injection site. Relationships between hyperinsulinemia and insulin resistance and risk of atherosclerosis and cancer: Although experimental studies have pointed to the relationship between atherosclerosis and hyperinsulinemia, clinical evidence is not sufficient. Insulin is an anabolic hormone. Insulin receptors are structurally similar to that of insulin-like growth hormone (e.g. IGF-1). The power of insulin correlates with its receptor affinity. Powerful insulins have higher affinity for insulin and IGF-1 receptors. Therefore the relationship between insulin and cancer risk has been considered for many years. However, because of conflicting data based on cross-sectional studies, the discussions about this issue still continue. But randomized clinical studies on this issue are lacking. 8.2 INSULIN TREATMENT PROTOCOLS Basal-Bolus Insulin Replacement Basal-bolus insulin replacement should be recommended in type 1 diabetes, GDM that cannot be controlled with diet and type 2 diabetes with decreased endogenous insulin reserve. It can be applied in the following ways: A. Multiple Subcutaneous Insulin Injections (MSII) Rapid/short-acting (bolus) insulin three times in a day preprandial plus intermediate/long-acting (basal) insulin (preferably in the evening) as a single dose. Rapid/short-acting (bolus) insulin three times in a day preprandial plus intermediate/long-acting (basal) insulin two times in a day. Premixed (biphasic) insulin analogs should be considered in patients with type 2 diabetes who have difficulty to implement basal bolus insulin therapy with two different insulin preparations. B. Continuous Subcutaneous Insulin Infusion (CSII) Continuous subcutaneous insulin infusion, using basal, bolus and adjustment doses via external pump, could be a solution to improve glycemic control (see Chapter 10).
4 Turk JEM 2010; 14: Suppl 40-6 The Principles of Insulin Therapy Insulin Supplement Therapy It is recommended in elderly patients with type 1 diabetes with complications or at high risk of hypoglycemia, GDM that cannot be controlled with diet, and some cases with type 2 diabetes. A. Biphasic Insulin Mixtures Intermediate/long-acting + rapid/short-acting premixed insulins two times in a day: Premixed insulin preparations can be used. Alternatively, patients may inject two different insulin. B. Basal insulin support Intermediate/long-acting (basal) insulin support once or twice a day (in type 2 diabetic patients and some GDM cases). There is not enough evidence about the safety of long-acting insulin analog during pregnancy, therefore glargine and detemir insulin should not be used in cases of pregestational diabetes and GDM Insulin Dose Calculation and Adjustment Initially it is adjusted per kilogram of body weight. Moreover, phenotype and physical activity status of individuals with diabetes, and presence of diabetes complications should be taken into consideration. Recommendations for calculation of insulin dose are given in Table 8.2. In general, maintenance of insulin dose for individuals with type 1 and type 2 diabetes is as follows: Type 1 diabetes; IU/kg/day Type 2 diabetes; IU/kg/day In basal bolus insulin regimen about half of daily requirement (40-60%) is calculated as basal and the remaining half (40-60%) as bolus dose. Basal insulin support; IU/kg/day can be given initially. Insulin injection time It depends on the type of insulin. Rapid-acting insulins are administered 5 to 15 minutes and short-acting insulins 30 minutes before meal. Insulin injection time can be changed according to blood glucose levels. For example, a meal may be delayed if preprandial PG level is higher than the targeted value. Insulin injections may be delayed to postprandial to avoid hypoglycemia in diabetic patients with extremely prolonged gastric emptying time. Table 8.2 Calculation of the insulin dose Phenotype Insulin dose (IU/kg/day) Normal weight patients Intense physical activity 0.3 Moderate physical activity 0.4 Mild physical activity 0.4 Obese patients Intense physical activity 0.5 Moderate physical activity 0.6 Mild physical activity 0.8 Renal failure Conditions with high risk of hypoglycemia Frequent, binge eaters Newly onset type 1 diabetes (<30 years of age) 0.3
5 44 The Principles of Insulin Therapy Turk JEM 2010; 14: Suppl Injection Methods A. Insulin Pens It allows safe and correct application of insulin, therefore it is more preferable. Most pens contain 300 IU (3 ml) of insulin and some of them are disposable, while others use replaceable cartridges. Insulin pens are calibrated for 1 IU, moreover pens calibrated for 0.5 IU are available for children. Insulin pen needles are in three lengths as 4 mm, 6 mm, 8 mm and 12 mm. Generally, 4, 6 or 8 mm needles are used. Obese individuals may require 12 mm-length needles. B. Insulin Syringes This method is used less frequently in most developed countries as well as our country. Insulin syringes are available in three different sizes; 0.3, 0.5, and 1 ml. They are calibrated for 1 IU, and syringes calibrated for 0.5 IU are available for children and for patients more sensitive to insulin. In general syringes with 8 mm needles are in use but also 6 and 12 mm needles are available. Ten ml vials (containing 1000 IU insulin) are used for syringes. C. Insulin Pump Continuous subcutaneous insulin infusion (CSII) or insulin pump therapy will be discussed in detail in the following sections (see Chapter 10 The Principles of CSII) Insulin Storage Guidelines Unopened vials and cartridges can be stored at 2-8 o C in the refrigerator until the expiration date. Opened vials and cartridges can be used at room temperature up to 30 days. Intermediate/long-acting or premixed insulin preparations may lose their biological activity slightly 15 days after they have opened. This should be considered if glycemic control begins to deteriorate although patient s health condition has not changed Mixing of Insulin Preparations Short-acting and NPH insulins should be used immediately after mixing (However, some authors suggest that these mixtures can be kept in the refrigerator up to 2 weeks). Glargine and detemir insulins should not be mixed with other insulins Drugs that Interact with Insulin Given that some drugs in Table 8.3 may lead to hypoglycemia by increasing the effect of insulin whereas some others to hyperglycemia by reducing the effect of it (some of them by inducing insulin resistance) they require insulin dose adjustments.
6 Turk JEM 2010; 14: Suppl 40-6 The Principles of Insulin Therapy 45 Table 8.3 Drugs that Interact with Insulin A. Drugs increasing the hypoglycemic B. Drugs reducing the hypoglycemic effect and lowering glycemia effect and increasing glycemia β-blockers (*) Acetazolamide ACE-I Albuterol Alcohol Antiviral agents used in AIDS Anabolic steroids Asparaginase Calcium Calcitonin Chloroquine Corticosteroids Clofibrate Cyclophosphamide Clonidine Danazol Disopyramide Dextrothyroxine Fluoxetine Diazoxide Guanitidine Diltiazem Lithium carbonate Diuretics Mebendezole Dobutamine Monoamine oxidase inhibitors Epinephrine OADs Estrogen hormones Pentamidine (**) Ethacrynic acid Phenylbutazone Isoniazid Piridoxine Lithium carbonate Propoxyphene Morphine sulphate Salicylate Niacin Somatostatin analogs (Octreotide) Nicotine Sulfonamides Oral contraceptives Sulphynpirazone Phenytoin Tetracycline Somatropin Terbutaline Thiazide diuretics Thyroid hormones (*) They may delay the recovery from hypoglycemia. (**) Hypoglycemia is sometimes followed by hyperglycemia SEMT APPROACHES TO INSULIN TREATMENT AND RECOMMENDATIONS Basal-bolus (intensive) insulin therapy should be preferred to provide glycemic control in adults with type 1 diabetes, and in patients with type 2 diabetes whose beta cell reserves were depleted [For type 1 diabetic patients: Class A, Level 1A evidence; For type 2 diabetic patients: Class D, evidence-based consensus]. Insulin analogues are not superior to human insulin to obtain good glycemic control (A1C) [Class A, Level 1 evidence (2,3)]. Basal insulin can be used together with rapid-acting insulin analogues (aspart, glulisine, lispro) to reduce the risk of hypoglycemia and to provide PPG control while lowering A1C [Class B, Level 2 evidence (3,4)]. Long-acting insulin analogues (glargine, detemir) can be used as an alternative to NPH insulin for basal insulin support [Class B, Level 2 evidence (5-8)]. Long-acting insulin analogues (glargine, detemir) should not be used in pregnancy (Class D, evidence-based consensus). It has been shown in clinical trials that the risks of severe hypoglycemia and nocturnal hypoglycemia with basal insulin analogeus are slightly lower compared to NPH insulin: - to reduce the risk of severe hypoglycemia [For glargine: Class B, Level 2 evidence (9); For detemir: Class C, Level 3 evidence (10)]. - to reduce the risk of nocturnal hypoglycemia [For glargine: Class B, Level 2 evidence (10); For detemir: Class D, evidence-based consensus]. All individuals with type 1 diabetes should be evaluated about the risk of hypoglycemia, be counseled about the risk and prevention of insulin-induced hypoglycemia, and risk factors for severe hypoglycemia should be identified and addressed (Class D, evidence-based consensus). In individuals with hypoglycemia unawareness, the following strategies should be implemented to attempt to regain hypoglycemia awareness: - Increased frequency of SMBG, including periodic assessment at night (Class D, evidence-based consensus). Less strict glycemic control for a while (higher glycemia and A1C levels are targeted) until the patient is recovered [Class C, Level 3 evidence (11,12)].
7 46 The Principles of Insulin Therapy Turk JEM 2010; 14: Suppl 40-6 REFERENCES 1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993;329: Plank J, Siebenhofer A, Berghold A, et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005;165: Singh SR, Ahmad F, Lal A, et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009;180: Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006;(2):CD Warren E, Weatherley-Jones E, Chilcott J, et al. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess 2004;8: Wang F, Carabino JM, Vergara CM. Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther 2003;25: Dunn CJ, Plosker GL, Keating GM, et al. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs 2003;63: Chapman TM, Perry CM. Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs 2004;64: Mullins P, Sharplin P, Yki-Jarvinen H, et al. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007;29: Goldman-Levine JD, Lee KW. Insulin detemir a new basal insulin analog. Ann Pharmacother 2005;39: Liu D, McManus RM, Ryan EA. Improved counter-regulatory hormonal and symptomatic responses to hypoglycemia in patients with insulin-dependent diabetes mellitus after 3 months of less strict glycaemic control. Clin Invest Med 1996;19: Lingenfelser T, Buettner U, Martin J, et al. Improvement of impaired counterregulatory hormone response and symptom perception by short-term avoidance of hypoglycemia in IDDM. Diabetes Care 1995;18:321-5.
INSULIN OVERVIEW. Type Brand Name Onset Peak Duration Role in glucose management Page Rapid-Acting lispro min. 3-5 hrs min.
INSULIN OVERVIEW Type Brand Name Onset Peak Duration Role in glucose management Page Rapid-Acting lispro Humalog 15-30 min 30-90 min 3-5 hrs aspart glulisine Short-Acting Regular insulin NovoLog Apidra
More informationShort-acting insulins. Biphasic insulins. Intermediate- and long-acting insulins
Recommended Insulin Products This guideline states the Gloucestershire Joint Formulary recommended, first choice insulin products. The intention is to support the choice of treatment for new patients,
More informationSoliqua 100/33. (insulin glargine, lixisenatide) New Product Slideshow
Soliqua 100/33 (insulin glargine, lixisenatide) New Product Slideshow Introduction Brand name: Soliqua 100/33 Generic name: Insulin glargine (rdna origin), lixisenatide Pharmacological class: Human insulin
More informationType I Type II Insulin Resistance
Insulin An aqueous hormonal solution made in the pancreas. Affects metabolism by allowing glucose to leave the blood and enter the body cells, preventing hyperglycemia. It is measured in units, e.g. 100
More informationXultophy 100/3.6. (insulin degludec, liraglutide) New Product Slideshow
Xultophy 100/3.6 (insulin degludec, liraglutide) New Product Slideshow Introduction Brand name: Xultophy Generic name: Insulin degludec, liraglutide Pharmacological class: Human insulin analog + glucagon-like
More informationFULL PRESCRIBING INFORMATION
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HUMULIN N safely and effectively. See full prescribing information for HUMULIN N. HUMULIN N (human
More informationFULL PRESCRIBING INFORMATION
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HUMULIN 70/30 safely and effectively. See full prescribing information for HUMULIN 70/30. HUMULIN
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationStarting and Helping People with Type 2 Diabetes on Insulin
Starting and Helping People with Type 2 Diabetes on Insulin Elaine Cooke, BSc(Pharm), RPh, CDE Pharmacist and Certified Diabetes Educator Maple Ridge, BC Objectives After attending this session, participants
More informationInsulin Therapy Management. Insulin Therapy
Insulin Therapy Management Insulin Therapy Contents Insulin and its effect on glycemic control Physiology of insulin secretion Insulin pharmacokinetics and regimens Insulin dose adjustment for pregnancy
More informationInsulin analogues Das PP, Datta PG
The ORION Medical Journal 2007 Sep;28:497-500 Insulin analogues Das PP, Datta PG Introduction Diabetes mellitus is a very big challenge for our medical science. To overcome this problem we need newer generation
More informationINSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More informationHUMULIN R U-500 (insulin human injection), for subcutaneous use Initial U.S. Approval: 1994
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HUMULIN R U-500 safely and effectively. See full prescribing information for HUMULIN R U-500. HUMULIN
More informationInsulin therapy in gestational diabetes mellitus
Insulin therapy in gestational diabetes mellitus October 15, 2015 Kyung-Soo Kim Division of Endocrinology & Metabolism, Department of Internal Medicine, CHA Bundang Medical Center, CHA University Contents
More information75% INSULIN LISPRO PROTAMINE SUSPENSION AND 25% INSULIN LISPRO INJECTION (rdna ORIGIN) 100 UNITS PER ML (U-100)
1 PV 5552 AMP HUMALOG Mix75/25TM 75% INSULIN LISPRO PROTAMINE SUSPENSION AND 25% INSULIN LISPRO INJECTION (rdna ORIGIN) 100 UNITS PER ML (U-100) DESCRIPTION Humalog Mix75/25 [75% insulin lispro protamine
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationTips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital
Tips and Tricks for Starting and Adjusting Insulin MC MacSween The Moncton Hospital Progression of type 2 diabetes Beta cell apoptosis Natural History of Type 2 Diabetes The Burden of Treatment Failure
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationBEST 4 Diabetes. Optimisation of insulin module
BEST 4 Diabetes Optimisation of insulin module Confidence and competence Where would you rate yourself? Why do all of our patient not achieve optimal blood glucose control? Insulin Therapy Goals and Purpose
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationINSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد
INSULIN THERAY DIABETES1 IN TYPE دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد Goals of management Manage symptoms Prevent acute and late complications Improve quality of life Avoid
More informationBEST 4 Diabetes. Optimisation of insulin module
BEST 4 Diabetes Optimisation of insulin module Confidence and competence Where would you rate yourself? Why do all of our patient not achieve optimal blood glucose control? Insulin Therapy Goals and Purpose
More informationInsulin Basic facts. Patient Education Patient Care Services. What is insulin? What types of insulin are there? Basal Insulin
Patient Education Insulin Basic facts Insulin is a protein made by the pancreas that allows your cells to use glucose for energy. There are different types of insulin: Basal long-acting insulin that controls
More informationInsulin Management. By Susan Henry Diabetes Specialist Nurse
Insulin Management By Susan Henry Diabetes Specialist Nurse The Discovery of Insulin - 1921 - Banting & Best University Of Toronto Discovered hormone insulin in pancreatic extract of dog - Marjorie the
More informationDrugs used in Diabetes. Dr Andrew Smith
Drugs used in Diabetes Dr Andrew Smith Plan Introduction Insulin Sensitising Drugs: Metformin Glitazones Insulin Secretagogues: Sulphonylureas Meglitinides Others: Acarbose Incretins Amylin Analogues Damaglifozin
More informationExogenous Insulin in type 2 DM
Exogenous Insulin in type 2 DM Russell Scott 2015 Part 1: Some basic biochemistry for Insulin absorption and action MY CHECK LIST Factors influencing insulin action: Forgets to inject Amount given Timing
More informationGuide to Starting and Adjusting Insulin for Type 2 Diabetes*
Guide to Starting and Adjusting Insulin for Type 2 Diabetes* www.cadth.ca * Adapted from Guide to Starting and Adjusting Insulin for Type 2 Diabetes, 2008 International Diabetes Center, Minneapolis, MN.
More informationInjectable Therapies in Diabetes
Injectable Therapies in Diabetes Diabetes Specialist Nurse Joyce Robson Learning Outcomes Think about the place of injectible therapies in diabetes Insulin therapy GLP1 antagonists Consider commonly used
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) June 2017 Review: June 2020 (earlier if required see recommendations) Bulletin 255: Insulin aspart New Formulation - Fiasp JPC Recommendations:
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationInsulin Regimens: Hitting Glycemia Targets
Insulin Regimens: Hitting Glycemia Targets Grant Kelley MD March 1 st, 2018 Faculty Disclosure: Financial relationships with commercial interests None Overview Mortality and Morbidity Insulin and Insulin
More informationHow they work and when to take them. Diabetes Medications
How they work and when to take them Diabetes Medications BIGUANIDES Metformin Actions Slows down the release of glucose from the liver. Helps the bodies cells become more sensitive to insulin. Pros Weight
More informationBasal-Bolus Insulin Therapy. Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January
Basal-Bolus Insulin Therapy Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January 18 2018 Terminology No longer using the term diabetic. Diabetes does not define people. People with diabetes are individuals
More informationPRODUCT MONOGRAPH APIDRA. insulin glulisine injection (rdna origin) Solution for injection 100 U/mL. ATC code: A10AB. Antidiabetic Agent
PRODUCT MONOGRAPH APIDRA insulin glulisine injection (rdna origin) Solution for injection 100 U/mL ATC code: A10AB Antidiabetic Agent Short-acting Recombinant Human Insulin Analogue sanofi-aventis Canada
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NOVOLOG safely and effectively. See full prescribing information for NOVOLOG. NOVOLOG (insulin aspart
More informationBasal Bolus Insulin Therapy Frequently Asked Questions
1. What is Basal Bolus Insulin Therapy (BBIT)? 2. What evidence supports the use of subcutaneous Basal Bolus Insulin Therapy? 3. Does Basal Bolus Insulin Therapy apply to all patients? 4. What s wrong
More informationFaculty. Concentrated Insulin: Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management. Disclosures. Learning Objectives
Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management Faculty Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Professor of Pharmacy Practice Associate Director of Experiential
More informationPHARMACISTS INTERACTIVE EDUCATION CASE STUDIES
PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More informationPHARMACISTS INTERACTIVE EDUCATION CASE STUDIES
PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More informationEndo 2 SLO Practice (online) Page 1 of 7
Endo 2 SLO Practice (online) Page 1 of 7 1. A long- acting insulin, like Lantus is for? A. When the next meal is within 30-60 minutes of the injection B. Over night use or for ½ of the day often combined
More informationHypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier??
Hypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier?? Moshe Phillip Institute of Endocrinology and Diabetes National Center of Childhood Diabetes Schneider
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Humalog 100 units/ml, solution for injection in vial 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 2.1 General description Humalog
More informationPranay wal et al, /J. Pharm. Sci. & Res. Vol.2(5), 2010,
Comparative efficacy of humalog mix 75/25 with human Insulin. Pranay wal 1 *, Ankita wal 2, Shivangi Srivastava 2,Abhinav srivastava 2, Umeshwar Pandey 3, Tarun Jain 1, Awani k Rai 2. 1 Jodhpur National
More informationNovoLog (insulin aspart [rdna origin] injection) solution for subcutaneous use Initial U.S. Approval: 2000
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NovoLog safely and effectively. See full prescribing information for NovoLog. NovoLog (insulin aspart
More informationA Fact Sheet for Parents and Carers Insulin and Diabetes
A Fact Sheet for Parents and Carers Insulin and Diabetes In type 1 diabetes the body stops producing insulin. Insulin therapy is essential in the treatment of type 1 diabetes, together with a healthy eating
More informationDiabetes Head to Toe May 31, 2017
Innovations in Insulin Joanne Reid RN CDE jmreid@gbhs.on.ca Danielle Benedict RPh Outline Setting the stage Insulin as pancreas replacement therapy Commonly used insulins New insulins Case Studies Dosing
More informationNewer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationLegal Status Indication Treatment of Type 1 and Type 2 diabetes
New Medicine Report (Adopted by the CCG until review and further notice) Document Status Recombinant human insulin analogues Following Suffolk D&TC Meeting Traffic Light Decision Green Date of Last Revision
More informationMANAGEMENT OF TYPE 1 DIABETES MELLITUS
MANAGEMENT OF TYPE 1 DIABETES MELLITUS INVESTIGATIONS AND TREATMENT MANSI NAIK VII SEMESTER INVESTIGATIONS FASTING BLOOD SUGAR PLASMA GLUCOSE HEMOGLOBIN A 1c SYMPTOMS OF TYPE 1 DIABETES MELLITUS Polyuria
More informationComparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary
Number 14 Effective Health Care Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Background and Key Questions
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationMANAGEMENT OF DIABETES IN PREGNANCY
MANAGEMENT OF DIABETES IN PREGNANCY Ministry of Health Malaysia Malaysian Endocrine & Metabolic Society Perinatal Society of Malaysia Family Medicine Specialists Association of Malaysia Academy of Medicine
More informationInjectable Therapies in Diabetes
Injectable Therapies in Diabetes Diabetes Specialist Nurse Joyce Robson Learning Outcomes Think about the place of injectible therapies in diabetes Think about when / why patients require insulin therapy
More informationPRODUCT INFORMATION APIDRA
PRODUCT INFORMATION APIDRA NAME OF THE DRUG Insulin glulisine DESCRIPTION APIDRA [insulin glulisine injection {rdna origin}] is a recombinant human insulin analogue produced by recombinant DNA technology.
More informationThis certificate-level program is non-sponsored.
Program Name: Diabetes Education : A Comprehensive Review Module 5 Intensive Insulin Therapy Planning Committee: Michael Boivin, B. Pharm. Johanne Fortier, BSc.Sc, BPh.LPh, CDE Carlene Oleksyn, B.S.P.
More informationObjectives. Navigating New Insulins. Disclosures. Diabetes: The Stats. Normal Insulin Release Individuals without diabetes. History of Insulin 5/23/17
Objectives Compare and contrast currently available products. Navigating New s Diana Isaacs, PharmD, BCPS, BC-ADM, CDE Clinical Pharmacy Specialist Cleveland Clinic Diabetes Center Determine the factors
More informationInjecting Insulin into Out Patient Practice
Injecting Insulin into Out Patient Practice Kathleen Colleran, MD Associate Professor UNMHSC 4/22/10 Overview Natural history of Type 2 diabetes Reasons clinicians are reluctant to start insulin therapy
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationADMELOG, NOVOLIN, NOVOLOG, and FIASP
ADMELOG, NOVOLIN, NOVOLOG, and FIASP Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationA STEP-Wise Approach. A1C Reductions. With NovoLog as Part of a Basal Bolus Therapy
A STEP-Wise Approach Indications and Usage NovoLog is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. Important Safety Information NovoLog is contraindicated
More informationMixed Insulins Pick Me
Mixed Insulins Pick Me Alvin Goo, PharmD Clinical Associate Professor University of Washington School of Pharmacy and Department of Family Medicine Objectives Critically evaluate the evidence comparing
More informationDEMYSTIFYING INSULIN THERAPY
DEMYSTIFYING INSULIN THERAPY ASHLYN SMITH, PA-C ENDOCRINOLOGY ASSOCIATES SCOTTSDALE, AZ SECRETARY, AMERICAN SOCIETY OF ENDOCRINE PHYSICIAN ASSISTANTS ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING
More informationLearning Objectives. Are you ready for more insulin formulations?
Are you ready for more insulin formulations? Shara Elrod, PharmD, BCACP, BCGP Learning Objectives Review pharmacology and dosing of new insulin formulations Compare and contrast new insulin formulations
More informationInsulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children
Insulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children December 2008 This technology summary is based on information available at the time of research and a limited literature
More informationNew basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011
New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 Presenter Disclosure I have received the following
More informationWhat do you need to know before you go home?
What do you need to know before you go home? What is Insulin Types of Insulin Injection Sites How to Inject Insulin Correctly Low Blood Sugar and Treatment Sick Day Management After leaving the Hospital:
More informationFor the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.
HUMALOG MIX 25 & HUMALOG MIX 50 1. NAME OF THE MEDICINAL PRODUCT Humalog Mix25 100 U/ml suspension for injection in cartridge Humalog Mix50 100U/ml suspension for injection in cartridge 2. Qualitative
More informationInsulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products
Insulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products FDA LABELED INDICATIONS 1-13,16-21 Rapid-Acting Indication Onset Peak Duration Insulins Admelog (insulin
More informationInsulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products
Insulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products FDA LABELED INDICATIONS 1-13,16-20 Rapid-Acting Indication Onset Peak Duration Insulins Fiasp (insulin
More informationassociated with serious complications, but reduce occurrences with preventive measures
Wk 9. Management of Clients with Diabetes Mellitus 1. Diabetes Mellitus body s inability to metabolize carbohydrates, fats, proteins hyperglycemia associated with serious complications, but reduce occurrences
More informationHUMALOG Pen Eli Lilly
HUMALOG Pen Eli Lilly 100 U/ml solution for injection insulin lispro (rdna origin) 1. NAME OF THE MEDICINAL PRODUCT Humalog Pen 100 U/ml, solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationThe principles of insulin adjustment guidance
The principles of insulin adjustment guidance Tips for insulin titration Blood glucose (BG) monitoring is needed to help identify the efficacy of treatment in diabetes. Monitor blood glucose according
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More information8/13/2016. Insulin Basics. Rapid-Acting Insulin Analogs. Current Insulin Products and Pens. Basal Insulin Analogs. History of Insulin Therapy
Insulin Basics Anabolic hormone involved in metabolism Following carbohydrate ingestion insulin release is stimulated Suppresses hepatic glucose production Stimulates peripheral glucose uptake Commercially-available
More informationInjectable Therapies in Diabetes
Injectable Therapies in Diabetes Diabetes Specialist Nurse Linda Burns Learning Outcomes Understand the place of injectible therapies in diabetes Understand when patients may require insulin therapy Consider
More informationUpdate on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy
Update on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy Jerry Meece, BPharm, CDE, FACA, FAADE Director of Clinical Services Plaza Pharmacy and Wellness Center Gainesville,
More informationDiabetes in Pregnancy
Diabetes in Pregnancy Ebony Boyce Carter, MD, MPH Division of Maternal Fetal Medicine Washington University School of Medicine Disclosures I have no financial disclosures to report. Objectives Review the
More informationNph insulin conversion to lantus
Nph insulin conversion to lantus Search 26-2-2003 RESPONSE FROM AVENTIS. We appreciate the opportunity to respond to Dr. Grajower s request for information regarding Lantus ( insulin glargine [rdna origin.
More informationGet started with Humulin R U-500. Savings information INSIDE!
Get started with Humulin R U-500 Savings information INSIDE! Take charge with the only 5x concentrated insulin proven to lower A1C with the potential for fewer injections.* With U-500, you can inject up
More informationDisclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2
Therapy For Diabetes Michigan Association of Osteopathic Family Physicians Mid-Winter Family Medicine Update Shanty Creek Resort, MI January 19-22nd 2017 Michael R. Brennan D.O., M.S., F.A.C.E Director
More informationConverting lantus to humalog 75 25
P ford residence southampton, ny Converting lantus to humalog 75 25 This page includes the following topics and synonyms: Insulin Dosing in Type 2 Diabetes, Insulin Dosing in Type II Diabetes. Thiazide
More informationCONTRAINDICATIONS Do not use in patients with hypersensitivity to LANTUS or one of its excipients (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (insulin glargine [rdna origin] injection)
More informationDIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013
DIABETES Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes November 2013 mbruskewitz@outlook.com Objectives Part 1 Overview of Endocrine Physiology Pathophysiology of Diabetes Diabetes
More informationThe York Diabetes Care Model
This Session The York Diabetes Care Model The annual review what s it for and how to do it How to make the diagnosis of diabetes and who to test Categorisation of diabetes at diagnosis Basics of Insulin
More informationINSULIN GLARGINE INJECTION I.P. LANTUS
For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory This package insert is continually updated: Please read carefully before using a new pack INSULIN GLARGINE INJECTION
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG. HUMALOG (insulin lispro
More informationSHARED CARE GUIDELINE ON THE USE OF FIASP FOR THE MANAGEMENT OF TYPE 1 DIABETES IN ADULTS
SHARED CARE GUIDELINE ON THE USE OF FIASP FOR THE MANAGEMENT OF TYPE 1 DIABETES IN ADULTS INDICATION Fiasp is indicated for the treatment of diabetes mellitus in adults. Special Note: DMAG has approved
More informationDiabetes mellitus is associated with serious long-term
CMAJ Research Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis Sumeet R. Singh BScPhm MSc, Fida Ahmad MSc, Avtar Lal MD PhD, Changhua Yu MD MSc, Zemin Bai
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationAdvances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the US FDA estimated
More informationVO: Toujeo has the same number of units as Lantus in one-third the injection volume. 1
From the makers of Lantus, comes Toujeo. For patients needing basal insulin, Toujeo. An insulin of today All day. Every day. Toujeo has the same number of units as Lantus in one-third the injection volume.
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
Types of Insulin Rapid-acting insulin: lispro (Humalog), aspart (NovoRapid), glulisine (Apidra) Regular short-acting insulin: Humulin R, Novolin ge Toronto, Hypurin Regular Basal insulin: NPH (Humulin
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ADMELOG safely and effectively. See full prescribing information for ADMELOG. ADMELOG (insulin lispro
More informationDiabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE
Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized
More informationIn-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University
In-Hospital Management of Diabetes Dr Benjamin Schiff Assistant Professor McGill University No conflict of interest to declare CLINICAL SCENARIO 62 y/o male with hx of DM 2, COPD, and HT is admitted with
More informationInsulin Analogs & Premixed Insulin Analogs
Rationale for the Development and Clinical Use of Insulin Analogs & Premixed Insulin Analogs A continuing education monograph for pharmacists, nurses, and dietitians this CE activity can also be completed
More informationDosage and Administration (2.1, 2.4) 3/2018 Warnings and Precautions (5.1, 5.4) 3/2018
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TOUJEO safely and effectively. See full prescribing information for TOUJEO. TOUJEO (insulin glargine
More information